Trastuzumab-Induced Cardiomyopathy. [Review] 

 -  2019 
<br/><br/> Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). Its overexpression occurs in 25% of breast cancers and is associated with aggressive tumor characteristics and poor prognosis in absence of targeted therapy. Trastuzumab dramatically improves HER2-positive breast cancer outcomes; however, its clinical use is associated with left ventricular dysfunction and heart failure. Patients receiving trastuzumab or other HER2-targeted therapies undergo routine cardiac function assessment. Holding and/or stopping trastuzumab treatment in the setting of left ventricular dysfunction is recommended. This article summarizes the role of trastuzumab in cancer treatment, the mechanisms of trastuzumab-induced cardiotoxicity, recent clinical investigations, and current controversies. Copyright (c) 2019 Elsevier Inc. All rights reserved. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>0733-8651 
<br/><br/><label>Standard No.: </label>10.1016/j.ccl.2019.07.005 [doi] S0733-8651(19)30054-2 [pii] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Breast Neoplasms/dt [Drug Therapy]<br/>*Cardiomyopathies/ci [Chemically Induced]<br/>*Trastuzumab/ae [Adverse Effects]<br/>Antineoplastic Agents, Immunological/ae [Adverse Effects]<br/>Cardiomyopathies/ep [Epidemiology]<br/>Cardiotoxicity<br/>Female<br/>Global Health<br/>Humans<br/>Incidence
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Heart & Vascular Institute
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Review